Welcome to our dedicated page for Immunome news (Ticker: IMNM), a resource for investors and traders seeking the latest updates and insights on Immunome stock.
Immunome, Inc. (Nasdaq: IMNM) is a clinical-stage targeted oncology company whose news flow is closely tied to the progress of its cancer drug pipeline and capital markets activity. Press releases and updates frequently describe advances in its lead programs, including varegacestat, an investigational oral gamma secretase inhibitor for desmoid tumors, and IM-1021, a ROR1-targeted antibody-drug conjugate (ADC) that uses the company’s proprietary HC74 TOP1 inhibitor payload.
Investors following IMNM news can expect detailed announcements on clinical trial milestones, such as topline data from the global Phase 3 RINGSIDE trial of varegacestat, which met its primary and key secondary endpoints in patients with progressing desmoid tumors. Immunome also issues updates on early clinical activity for IM-1021 in B-cell lymphoma, IND clearance for the FAP-targeted radioligand IM-3050, and progress across its preclinical ADC programs IM-1617, IM-1335 and IM-1340.
In addition to R&D updates, Immunome regularly reports financial and corporate developments. Recent news includes quarterly financial results, guidance on cash runway, and details of a follow-on public offering of common stock under an effective shelf registration statement. The company also discloses inducement stock option grants under its 2024 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4), as well as participation in major healthcare and investor conferences.
This IMNM news page aggregates these disclosures so readers can track trial readouts, regulatory plans such as the intended NDA submission for varegacestat, financing transactions, and corporate presentations in one place. For investors, analysts and healthcare professionals, the stream of Immunome news provides insight into the evolution of its targeted oncology pipeline and its use of capital to support ongoing development.
Immunome (NASDAQ:IMNM) has entered into a research collaboration agreement with Infinimmune for novel antibody discovery and optimization. The partnership leverages Infinimmune's GLIMPSE™ and Anthrobody® platforms to transform early-stage antibodies into development-ready therapeutic candidates.
Under the agreement, Immunome receives target exclusivity, with Infinimmune handling antibody discovery and optimization while Immunome will manage development and commercialization of resulting candidates. Financial terms were not disclosed.
Immunome (Nasdaq: IMNM), a biotechnology company specializing in targeted cancer therapies, has announced inducement grants to new employees. The Compensation Committee approved non-statutory stock options for 117,000 shares of common stock to 8 new employees under the company's 2024 Inducement Plan.
The stock options have an exercise price of $9.28 per share, based on the company's closing price on September 2, 2025. The options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over the following 36 months, contingent on continued employment.
Immunome (NASDAQ:IMNM), a biotechnology company specializing in targeted cancer therapies, has announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference. The company's management will deliver a presentation on Tuesday, September 9, 2025, at 1:00 p.m. Eastern Time.
Investors and interested parties can access the presentation through a live audio webcast available on the Investor Relations section of Immunome's website. The presentation recording will remain accessible for approximately 30 days following the live event.
Immunome (Nasdaq: IMNM), a biotechnology company developing targeted cancer therapies, reported its Q2 2025 financial results and pipeline updates. The company's cash position of $268.0 million is expected to fund operations into 2027.
Key pipeline developments include: varegacestat's upcoming Phase 3 RINGSIDE topline data expected by end of 2025 and recent European Medicines Agency Orphan Drug Designation; IM-1021's ongoing Phase 1 trial reaching its third dose level; and IM-3050's IND clearance with Phase 1 trial initiation planned for late 2025. Three additional preclinical ADCs (IM-1617, IM-1340, and IM-1335) are undergoing IND-enabling work.
Q2 2025 financials showed R&D expenses of $40.5 million and G&A expenses of $10.0 million, with a net loss of $43.4 million.
Immunome (Nasdaq: IMNM), a biotechnology company developing targeted cancer therapies, has granted inducement stock options to 5 new employees under its 2024 Inducement Plan. The Compensation Committee approved options to purchase 39,000 shares of common stock at an exercise price of $10.59 per share.
The stock options will vest over a four-year period, with 25% vesting after one year and the remaining balance vesting monthly over the following 36 months, contingent on continued employment.
Immunome (Nasdaq: IMNM), a biotechnology company specializing in targeted cancer therapies, announced inducement grants to 8 new employees under its 2024 Inducement Plan. The Compensation Committee approved non-statutory stock options to purchase 125,500 shares of common stock at an exercise price of $8.47 per share.
The stock options will vest over a four-year period, with 25% vesting after one year and the remaining balance vesting monthly over the following 36 months, contingent on continued employment.
Immunome (NASDAQ: IMNM), a biotechnology company specializing in targeted cancer therapies, has announced its participation in two upcoming investor conferences. The company will present at the TD Cowen 6th Annual Oncology Innovation Summit on May 27, 2025, from 6:30 AM to 7:00 AM PT, and at the Goldman Sachs 46th Annual Global Healthcare Conference on June 10, 2025, from 11:00 AM to 11:35 AM PT. Live webcasts and 30-day replay links for both presentations will be accessible through the events section of Immunome's investor website.
Immunome (NASDAQ: IMNM) reported its Q1 2025 financial results and provided updates on its cancer therapy pipeline. The company's cash position stood at $317.3 million, including $161.7 million from January 2025 financing, expected to fund operations into 2027. Q1 2025 resulted in a net loss of $41.6 million, with R&D expenses of $36.9 million and G&A expenses of $10.7 million.
Key pipeline updates include: completion of enrollment for Phase 3 RINGSIDE Part B study of varegacestat for desmoid tumors, with topline data expected in H2 2025; ongoing Phase 1 trial of IM-1021 (ROR1 ADC) in solid tumors and lymphoma; IND clearance for IM-3050 (FAP radiotherapy) with clinical trial expected in H2 2025; and continued IND-enabling work for three preclinical ADCs (IM-1617, IM-1335, and IM-1340) incorporating HC74 technology.
Immunome (NASDAQ: IMNM), a biotechnology company specializing in targeted cancer therapies, announced inducement grants to nine new employees on May 1, 2025. The Compensation Committee approved non-statutory stock options to purchase 164,500 shares of common stock under the Company's 2024 Inducement Plan.
The stock options have an exercise price of $8.86 per share, matching the company's closing price on May 1, 2025. The options will vest over four years, with 25% vesting after one year and the remaining balance vesting monthly over 36 months, contingent on continued employment.